NeuroSense Therapeutics’ (NRSN) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of NeuroSense Therapeutics (NASDAQ:NRSN) in a report published on Wednesday,Benzinga reports. D. Boral Capital currently has a $14.00 price objective on the stock.

Other equities research analysts have also issued reports about the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a report on Monday, December 29th. Roth Mkm assumed coverage on shares of NeuroSense Therapeutics in a research report on Tuesday, March 10th. They issued a “buy” rating and a $3.00 price objective for the company. Finally, Wall Street Zen raised NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.50.

NeuroSense Therapeutics Price Performance

NeuroSense Therapeutics stock opened at $0.73 on Wednesday. The company’s 50 day simple moving average is $0.89 and its 200 day simple moving average is $1.00. NeuroSense Therapeutics has a fifty-two week low of $0.63 and a fifty-two week high of $2.60.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Two Sigma Investments LP bought a new stake in shares of NeuroSense Therapeutics during the third quarter worth $26,000. Jane Street Group LLC bought a new stake in NeuroSense Therapeutics during the second quarter worth about $54,000. Squarepoint Ops LLC raised its stake in shares of NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after purchasing an additional 45,450 shares in the last quarter. Finally, Yorkville Advisors Global LP bought a new stake in NeuroSense Therapeutics during the fourth quarter worth $77,000. Institutional investors own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.